Companies: 48,874 Total Market Cap: 132460447025120.92

Chugai Pharmaceutical

OTC-CHGCY
Healthcare Drug Manufacturers - General
Rank #230
Market Cap 86.98 B
Volume 3,411
Price 26.38
Change (%) 2.09%
Country or region Japan Japan

Chugai Pharmaceutical's latest marketcap:

86.98 B

As of 05/19/2025, Chugai Pharmaceutical's market capitalization has reached $86.98 B. According to our data, Chugai Pharmaceutical is the 230th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.

Market Cap 86.98 B
Revenue (ttm) 8.16 B
Net Income (ttm) 2.74 B
Shares Out 0
EPS (ttm) 1.66
Forward PE 0.00
Ex-Dividend Date 06/27/2025
Earnings Date 04/24/2025
Market Cap Chart
Data Updated: 05/19/2025

Chugai Pharmaceutical's yearly market capitalization.

Chugai Pharmaceutical has seen its market value drop from $87.57 B to $86.98 B since 2020, representing a total decrease of 0.67% and an annual compound decline rate (CAGR) of 0.15%.
Date Market Cap Change (%)
05/19/2025 $86.98 B 30.18%
12/30/2024 $73.28 B 17.53%
12/29/2023 $62.35 B 48.41%
12/30/2022 $42.01 B -21.23%
12/30/2021 $53.34 B -39.09%
12/30/2020 $87.57 B

Company Profile

About Chugai Pharmaceutical Co., Ltd.

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, is a leading pharmaceutical company engaged in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally.

Key Products

  • Oncology Products: Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Perjeta, Polivy, Tecentriq, and Phesgo.
  • Other Therapeutic Areas: Actemra (anti-IL-6 receptor), CellCept (immunosuppressant), Edirol (osteoporosis), Enspryng (anti-IL-6 receptor), Evrysdi (spinal muscular atrophy), Hemlibra (anti-coagulation), Mircera (erythropoiesis-stimulating), PiaSky (anti-complement), Ronapreve (anti-SARS-CoV-2), Tamiflu (anti-influenza), and Vabysmo (anti-VEGF/Ang-2).

Strategic Partnerships

The company maintains strategic alliances with the Roche Group and collaborates with Araris Biotech AG to develop antibody-drug conjugates (ADCs) using Araris' AraLinQ technology.

Company Background

Founded in 1925 and headquartered in Chuo-ku, Japan, Chugai Pharmaceutical operates as a subsidiary of Roche Holding Ltd.

Frequently Asked Questions

As of 05/19/2025, Chugai Pharmaceutical (including the parent company, if applicable) has an estimated market capitalization of $86.98 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.

Chugai Pharmaceutical global market capitalization ranking is approximately 230 as of 05/19/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.

Stock Detail

Country or region Japan
Founded 1925
IPO Date n/a
Employees 5,026
CEO Osamu Okuda
Sector Healthcare
Industry Drug Manufacturers - General
Address Nihonbashi Mitsui Tower
Chuo, 103-8324
Japan
Website https://www.chugai-pharm.co.jp
People Also Watch
Eli Lilly
755.11 2.09%
JNJ
152.49 2.09%
AbbVie
185.71 2.09%
Novo Nordisk
67.02 2.09%